Examples of recent publications worked on:

Examples of recent publications worked on:


  1. Sturkenboom M, Braeye T, van der Aa L, Danieli G, Dodd C, Duarte-Salles T, et al. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. Vaccine. 2020 pii: S0264-410X(20)30153-5. doi: 10.1016/j.vaccine.2020.01.100. [See on PubMed]
  2. Pal S, Ausar SF, Tifrea DF, Cheng C, Gallichan S, Sanchez V, et al. Protection of outbred mice against a vaginal challenge by a Chlamydia trachomatis serovar E recombinant major outer membrane protein vaccine is dependent on phosphate substitution in the adjuvant. Hum Vaccin Immunother. 2020:2;1-11 doi: 10.1080/21645515.2020.1717183. [Epub ahead of print]. [See on PubMed]
  3. Marius M, Vacher F, Bonnevay T. Comparison of LAL and recombinant Factor C endotoxin testing assays in human vaccines with complex matrices. PDA J Pharm Sci Technol. 2020 pii: pdajpst.2019.010389. doi: 10.5731/pdajpst.2019.010389. [Epub ahead of print] [See on PubMed].
  4. Lecouturier V, Pavot V, Berry C, Donadieu A, de Montfort A, Boudet F, et al. An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ vaccines. 2020;5:19. doi: 10.1038/s41541-020-0167-8. [See on PubMed]
  5. 2019

  6. Boissel JP, Cogny F, Marko N, Boissel FH. From clinical trial efficacy to real-life effectiveness: why conventional metrics do not work. Drugs Real World Outcomes. 2019;6(3):125-32. doi: 10.1007/s40801-019-0159-z. [see on PubMed]
  7. Weibel D, Dodd C, Mahaux O, Haguinet F, De Smedt T, Duarte-Salles T, et al. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination. Vaccine. 2019. pii: S0264-410X(19)30930-2. doi: 10.1016/j.vaccine.2019.07.039. [Epub ahead of print] [See on PubMed]
  8. Tin Tin Htar M, de Ridder M, Braeye T, Correa A, McGee C, de Lusignan S, et al. Advance system testing: Vaccine benefit studies using multi-country electronic health data – The example of pertussis vaccination. Vaccine. 2019. pii: S0264-410X(19)31167-3. doi: 10.1016/j.vaccine.2019.08.078. [Epub ahead of print] [See on PubMed]
  9. Sturkenboom M, Bahri P, Chiucchiuini A, Grove Krause T, Hahné S, Khromava A, et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine. 2019. pii: S0264-410X(19)31002-3. doi: 10.1016/j.vaccine.2019.07.081. [Epub ahead of print] [See on PubMed]
  10. Gini R, Dodd CN, Bollaerts K, Bartolini C, Roberto G, Huerta-Alvarez C, et al. Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project. Vaccine. 2019. pii: S0264-410X(19)30936-3. doi: 10.1016/j.vaccine.2019.07.045. [Epub ahead of print] [See on PubMed]
  11. Foucaut AM, Morelle M, Kempf-Lepine AS, Baudinet C, Meyrand R, Guillemaut S, et al. Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. Support Care Cancer. 2019;27(9):3449-61. doi: 10.1007/s00520-019-4658-y. [See on PubMed]
  12. Emborg H-D, Kahlert J, Braeye T, Bauwens J, Bollaerts K, Danieli G, et al. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example. Vaccine. 2019. pii: S0264-410X(19)30930-2. doi: 10.1016/j.vaccine.2019.07.039. [Epub ahead of print] [See on PubMed]
  13. Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg H-D, Danieli G, et al. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling. Vaccine. 2019. pii: S0264-410X(19)31243-5. doi: 10.1016/j.vaccine.2019.09.034. [Epub ahead of print] [See on PubMed]
  14. Bollaerts K, de Smedt T, McGee C, Emborg H-D, Villa M, Alexandridou M, et al. ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases. Vaccine. 2019. pii: S0264-410X(19)31051-5. doi: 10.1016/j.vaccine.2019.08.012. [Epub ahead of print] [See on PubMed]
  15. Bandiera S, Lebas A, Canizares-Martinello L, Guinchard F, Lyonnais C, Perrin S, et al. A single immunogenicity assay for testing potency of combination DTaP vaccines: Simultaneous quantitation of anti-DT, anti-TT, anti-PTxd and anti-FHA antibodies in Guinea-pig serum with a Luminex(R)-xMAP(R) bead-based serological assay. Biologicals. 2019;61:15-21. doi: 10.1016/j.biologicals.2019.08.002. [See on PubMed]
  16. Attwell K, Dube E, Gagneur A, Omer SB, Suggs LS, Thomson A. Vaccine acceptance: Science, policy, and practice in a ‘post-fact’ world. Vaccine. 2019;37(5):677-82. doi: 10.1016/j.vaccine.2018.12.014. [See on PubMed]
  17. 2018

  18. Mbelo S, Gay V, Blanchard S, Abachin E, Falque S, Lechenet J, et al. Development of a highly sensitive PCR/DNA chip method to detect mycoplasmas in a veterinary modified live vaccine. Biologicals. 2018. doi: 10.1016/j.biologicals.2018.05.002. [See on PubMed]
  19. Charretier C, Saulnier A, Benair L, Armanet C, Bassard I, Daulon S, et al. Robust real-time cell analysis method for determining viral infectious titers during development of a viral vaccine production process. J Virol Methods. 2018;252(Supplement C):57-64. doi: 10.1016/j.jviromet.2017.11.002. [See on PubMed]
  20. Ben Salah E, Dorgham K, Lesenechal M, Pease C, Allard L, Dragonetti C, et al. Assessment of an ultra-sensitive IFNgamma immunoassay prototype for latent tuberculosis diagnosis. Eur Cytokine Netw. 2018;29(4):136-45. doi: 10.1684/ecn.2018.0417. [See on PubMed]
  21. Arredondo-Garcia JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018. doi: 10.1016/j.cmi.2018.01.018. [See on PubMed]
  22. Abachin E, Convers S, Falque S, Esson R, Mallet L, Nougarede N. Comparison of reverse-transcriptase qPCR and droplet digital PCR for the quantification of dengue virus nucleic acid. Biologicals. 2018. doi: 10.1016/j.biologicals.2018.01.001. [See on PubMed]
  23. 2017

  24. Zerah L, Boddaert J, Leperre-Desplanques A, Bonnet-Zamponi D, Verny M, Deligne J, et al. Association between psychotropic and cardiovascular iatrogenic alerts and risk of hospitalizations in elderly people treated for dementia: a self-controlled case series study based on the matching of 2 French health insurance databases. J Am Med Dir Assoc. 2017;18(6):549.e1-.e13. doi: 10.1016/j.jamda.2017.02.001. [See on PubMed]
  25. Uhart M, Adam M, Dahlab A, Bresse X. Loss of chance associated with sub-optimal HPV vaccination coverage rate in France. Papillomavirus research (Amsterdam, Netherlands). 2017;3:73-9. doi: 10.1016/j.pvr.2017.02.004. [See on PubMed]
  26. 2016

  27. Pickering G, Marcoux M, Chapiro S, David L, Rat P, Michel M, et al. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33(8):575-83. doi: 10.1007/s40266-016-0389-7. [See on PubMed]
  28. Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis. 2016;10(7):e0004821. doi: 10.1371/journal.pntd.0004821. [See on PubMed]
  29. Bourmaud A, Soler-Michel P, Oriol M, Regnier V, Tinquaut F, Nourissat A, et al. Decision aid on breast cancer screening reduces attendance rate: results of a large-scale, randomized, controlled study by the DECIDEO group. Oncotarget. 2016;7(11):12885-92. doi: 10.18632/oncotarget.7332. [See on PubMed]
  30. Bourmaud A, Rousset V, Regnier-Denois V, Collard O, Jacquin JP, Merrouche Y, et al. Improving adherence to adjuvant endocrine therapy in breast cancer through a therapeutic educational approach: a feasibility study. Oncol Nurs Forum. 2016;43(3):E94-e103. doi: 10.1188/16.ONF.E94-E103. [See on PubMed]
  31. 2015

  32. Vukusic S, Durand-Dubief F, Benoit A, Marignier R, Frangoulis B, Confavreux C. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler. 2015;21(7):953-5. doi: 10.1177/1352458514554056. [See on PubMed]
  33. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113-23. doi: 10.1056/NEJMoa1411037. [See on PubMed]
  34. Ramdani-Bouguessa N, Ziane H, Bekhoucha S, Guechi Z, Azzam A, Touati D, et al. Evolution of antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolated from children with invasive and noninvasive pneumococcal diseases in Algeria from 2005 to 2012. New microbes and new infections. 2015;6:42-8. doi: 10.1016/j.nmni.2015.02.008. [See on PubMed]
  35. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015;32(1):10-30. doi: 10.1007/s12325-015-0178-4. [See on PubMed]
  36. Hadinegoro SR, Arredondo-Garcia JL, Cape ding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195-206. doi: 10.1056/NEJMoa1506223. [See on PubMed]
  37. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PloS One. 2015;10(7):e0132404. doi: 10.1371/journal.pone.0132404. [See on PubMed]
  38. Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial. Vaccine. 2015;33(6):789-95. doi: 10.1016/j.vaccine.2014.12.024. [See on PubMed]
  39. Breugelmans JG, Makanga MM, Cardoso AL, Mathewson SB, Sheridan-Jones BR, Gurney KA, et al. Bibliometric assessment of European and Sub-Saharan African research output on poverty-related and neglected infectious diseases from 2003 to 2011. PLoS Negl Trop Dis. 2015;9(8):e0003997. doi: 10.1371/journal.pntd.0003997. [See on PubMed]
  40. . Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, et al. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods. BMC Res Notes. 2015;8:291. doi: 10.1186/s13104-015-1231-8. [See on PubMed]
  41. Bordet R, Lang M, Dieu C, Billon N, Duffet JP. Early results from a multi-component French public-private partnership initiative to improve participation in clinical research - CeNGEPS: a prospective before-after study. BMC Med Res Methodol. 2015;15:67. doi: 10.1186/s12874-015-0044-8. [See on PubMed]
  42. 2014

  43. Weinke T, Glogger A, Bertrand I, Lukas K. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. ScientificWorldJournal. 2014;2014:749698. doi: 10.1155/2014/749698. [See on PubMed]
  44. Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine. 2014;32(18):2022-6. doi: 10.1016/j.vaccine.2014.02.008. [See on PubMed]
  45. Kahoul R, Gueyffier F, Amsallem E, Haugh M, Marchant I, Boissel FH, et al. Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population. J R Soc Interface. 2014;11(100):20140867. doi: 10.1098/rsif.2014.0867. [See on PubMed]
  46. Gervaix A, Ansaldi F, Brito-Avo A, Azzari C, Knuf M, Martinon-Torres F, et al. Pneumococcal vaccination in Europe: schedule adherence. Clin Ther. 2014;36(5):802-12.e1. doi: 10.1016/j.clinthera.2014.03.001. [See on PubMed]
  47. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. [See on PubMed]
  48. Bricout H, Perinetti E, Marchettini P, Ragni P, Zotti CM, Gabutti G, et al. Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. BMC Infect Dis. 2014;14:637. doi: 10.1186/s12879-014-0637-6. [See on PubMed]
  49. Bourmaud A, Pacaut C, Melis A, Tinquaut F, Magne N, Merrouche Y, et al. Is oral chemotherapy prescription safe for patients? A cross-sectional survey. Ann Oncol. 2014;25(2):500-4. doi: 10.1093/annonc/mdt553. [See on PubMed]
  50. 2013

  51. von Mackensen S, Campos IG, Acquadro C, Strandberg-Larsen M. Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents. Haemophilia. 2013;19(2):e73-83. doi: 10.1111/hae.12054. [See on PubMed]
  52. Tin Tin Htar M, Madhava H, Balmer P, Christopoulou D, Menegas D, Bonnet E. A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis. Adv Ther. 2013;30(8):748-62. doi: 10.1007/s12325-013-0051-2 [See on PubMed]
  53. Pichon S, Guinet-Morlot F, Minutello M, Donazzolo Y, Rouzier R, Chassard D, et al. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial. Vaccine. 2013;31(18):2295-301. doi: 10.1016/j.vaccine.2013.02.058. [See on PubMed]
  54. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127-51. doi: 10.1007/s12325-013-0007-6. [See on PubMed]
  55. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085-94. doi: 10.1586/14760584.2013.824709. [See on PubMed]
  56. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. [See on PubMed]
  57. Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48. [See on PubMed]
  58. Boissel J-P, Kahoul R, Marin D, Boissel F-H. Effect Model Law: An Approach for the Implementation of Personalized Medicine. J Pers Med. 2013;3(3):177. [See on PubMed]


  59. Tourasse C, Denier JF, Awada A, Gratadour AC, Nessah-Bousquet K, Gay J. Elastography in the assessment of sentinel lymph nodes prior to dissection. Eur J Radiol. 2012;81(11):3154-9. doi: 10.1186/1750-1172-8-48. doi: 10.1016/j.ejrad.2012.04.031. [See on PubMed]
  60. Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health economics review. 2012;2(1):19. doi: 10.1186/2191-1991-2-19. [See on PubMed]

Margaret Haugh's publications:

Margaret Haugh's publications:

  1. Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip(R)): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017;16(6):545-64. doi: 10.1080/14760584.2017.1324302. [See on PubMed]
  2. Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, et al. [The level of evidence for the use of biomarkers in the early detection of prostate cancer]. Ann Biol Clin (Paris). 2016;74(2):227-32. [See on PubMed]
  3. Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15:466. doi: 10.1186/s12889-015-1753-y. doi: 10.1098/rsif.2014.0867. [See on PubMed]
  4. Kahoul R, Gueyffier F, Amsallem E, Haugh M, Marchant I, Boissel FH, et al. Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population. J R Soc Interface. 2014;11(100):20140867. [See on PubMed]
  5. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132(3):895-915. doi: 10.1007/s10549-011-1837-z. [See on PubMed]
  6. Boissel JP, Kahoul R, Amsallem E, Gueyffier F, Haugh M, Boissel FH. Towards personalized medicine: exploring the consequences of the effect model-based approach. Per Med. 2011;8(5):581-6. [See on PubMed]
  7. Amsallem E, Kasparian C, Cucherat M, Chabaud S, Haugh M, Boissel JP, et al. Evaluation of two evidence-based knowledge transfer interventions for physicians. A cluster randomized controlled factorial design trial: the CardioDAS Study. Fundam Clin Pharmacol. 2007;21(6):631-41. [See on PubMed]
  8. Fervers B, Burgers JS, Haugh MC, Latreille J, Mlika-Cabanne N, Paquet L, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care. 2006;18(3):167-76. [See on PubMed]
  9. Haie-Meder C, Fervers B, Fondrinier E, Haugh M, Lhomme C, Guastalla JP. SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004. Ann Oncol. 2005;16(7):1100-8. [See on PubMed]
  10. Fervers B, Burgers JS, Haugh MC, Brouwers M, Browman G, Cluzeau F, et al. Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care. 2005;17(2):123-32. [See on PubMed]
  11. Spaeth D, Casadevall N, Daouphars M, Marchal C, Marec-Berard P, Fabre N, et al. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003]. Bull Cancer. 2004;91(2):179-88. [See on PubMed]
  12. Marchal C, Spaeth D, Casadevall N, Daouphars M, Marec-Berard P, Fabre N, et al. [Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietin-alpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-update 2003]. Cancer Radiother. 2004;8(3):197-206. [See on PubMed]
  13. Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T, et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol. 2004;22(10):2000-7. [See on PubMed]
  14. Boissel JP, Amsallem E, Cucherat M, Nony P, Haugh MC. Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation. Eur J Clin Pharmacol. 2004;60(9):609-16. [See on PubMed]
  15. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. [See on PubMed]
  16. Philip T, Fervers B, Haugh M, Otter R, Browman G. European cooperation for clinical practice guidelines in cancer. Br J Cancer. 2003;89 Suppl 1:S1-3. [See on PubMed]
  17. Fervers B, Philip T, Haugh M, Cluzeau F, Browman G. Clinical-practice guidelines in Europe: time for European co-operation for cancer guidelines. Lancet Oncol. 2003;4(3):139-40. [See on PubMed]
  18. Darmoni SJ, Amsallem E, Haugh M, Lukacs B, Leroux V, Thirion B, et al. Level of evidence as a future gold standard for the content quality of health resources on the internet. Methods Inf Med. 2003;42(3):220-5. [See on PubMed]
  19. Boissel JP, Haugh M, Fardeheb M, Nony P, Gueyffier F, Strang N. How should therapeutic information be transferred to users? Fundam Clin Pharmacol. 2003;17(4):495-503. [See on PubMed]
  20. Boissel JP, Cucherat M, Amsallem E, Nony P, Fardeheb M, Manzi W, et al. Getting evidence to prescribers and patients or how to make EBM a reality. Stud Health Technol Inform. 2003;95:554-9. [See on PubMed]
  21. McDonald S, Lefebvre C, Antes G, Galandi D, Gotzsche P, Hammarquist C, et al. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. Eval Health Prof. 2002;25(1):65-75. [See on PubMed]
  22. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13(3):708-14. [See on PubMed]
  23. Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol. 2002;147(1):118-21. [See on PubMed]
  24. Darmoni SJ, Haugh MC, Lukacs B, Boissel JP. Quality of health information about depression on internet. Level of evidence should be gold standard. BMJ. 2001;322(7298):1367. [See on PubMed]
  25. Slim K, Haugh M, Fagniez PL, Pezet D, Chipponi J. Ten-year audit of randomized trials in digestive surgery from Europe. Br J Surg. 2000;87(11):1585-6. [See on PubMed]
  26. Cucherat M, Haugh MC, Gooch M, Boissel JP. Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Homeopathic Medicines Research Advisory Group. Eur J Clin Pharmacol. 2000;56(1):27-33. [See on PubMed]
  27. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 2000;176:421-8. [See on PubMed]
  28. Haugh M, Fouque D. Evidence-based nephrology. Nephrol Dial Transplant. 1999;14 Suppl 3:38-41. [See on PubMed]
  29. Boissel JP, Cucherat M, Gueyffier F, Chatellier G, Buyse M, Li W, et al. [The problem of therapeutic efficacy indices. 1. Elements of the problem]. Therapie. 1999;54(2):203-7. [See on PubMed]
  30. Boissel JP, Buyse M, Cucherat M, Boutitie F, Gueyffier F, Chatellier G, et al. [The problem of therapeutic efficacy indices. 2. Description of the indices]. Therapie. 1999;54(3):309-14. [See on PubMed]
  31. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]. Therapie. 1999;54(4):405-11. [See on PubMed]
  32. Boissel JP, Cucherat M, Chatellier G, Buyse M, Li W, Boutitie F, et al. [Outline of the problem of indices of therapeutic efficacy. 4. Expression of efficacy when the underlying illness is incurable. Study Group for the Indices of Efficacy]. Therapie. 1999;54(5):519-23. [See on PubMed]
  33. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation. 1998;65(5):641-7. [See on PubMed]
  34. Nony P, Cucherat M, Haugh MC, Boissel JP. Standardization of terminology in meta-analysis: a proposal for working definitions. Fundam Clin Pharmacol. 1997;11(6):481-93. [See on PubMed]
  35. Leizorovicz A, Haugh MC, Mercier C, Boissel JP. Pre-hospital and hospital time delays in thrombolytic treatment in patients with suspected acute myocardial infarction. Analysis of data from the EMIP study. European Myocardial Infarction Project. Eur Heart J. 1997;18(2):248-53. [See on PubMed]
  36. Gueyffier F, Boissel JP, Haugh M. [The Hypertension Cochrane Review Group. Presentation and user's guide]. Arch Mal Coeur Vaiss. 1997;90(8):1159-63. [See on PubMed]
  37. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed. 1997;53(3):187-90. [See on PubMed]
  38. Boissel JP, Haugh MC. Clinical trial registries and ethics review boards: the results of a survey by the FICHTRE project. Fundam Clin Pharmacol. 1997;11(3):281-4. [See on PubMed]
  39. Maupas J, Haugh MC, Strang WN. [Information system for prescriptors and consumers]. Therapie. 1996;51(3):292-7. [See on PubMed]
  40. Haugh MC, Boissel JP, Pignon JP, Chalmers I. [The Cochrane Collaboration: the need for international collaboration]. Therapie. 1996;51(3):253-6. [See on PubMed]
  41. Fouque D, Laville M, Haugh M, Boissel JP. Systematic reviews and their roles in promoting evidence-based medicine in renal disease. Nephrol Dial Transplant. 1996;11(12):2398-401. [See on PubMed]
  42. Fareh S, Arnaud P, Fayn J, Nony P, Girard P, Haugh M, et al. Heterogeneous effect of quinidine on the ventricular depolarization process assessed by the spatial velocity electrocardiogram of the QRS complex. Preliminary report of a new investigative method. Cardiology. 1996;87(2):129-33. [See on PubMed]
  43. Nony P, Cucherat M, Haugh MC, Boissel JP. Critical reading of the meta-analysis of clinical trials. Therapie. 1995;50(4):339-51. [See on PubMed]
  44. Nony P, Boissel JP, Lievre M, Cucherat M, Haugh MC, Dayoub G. [Introduction to meta-analytic methodology]. Rev Med Interne. 1995;16(7):536-46. [See on PubMed]
  45. Lievre M, Gueret P, Gayet C, Roudaut R, Haugh MC, Delair S, et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995;25(1):92-7. [See on PubMed]
  46. Boissel JP, Durieu I, Girard P, Nony P, Chauvin F, Haugh M. Dose-ranging trials: guidelines for data collection and standardized descriptions. Control Clin Trials. 1995;16(5):319-30. [See on PubMed]
  47. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46(3):191-6. [See on PubMed]
  48. Nony P, Boissel JP, Girard P, Lion L, Haugh MC, Fareh S, et al. The role of an initial single-blind placebo period in phase I clinical trials. Fundam Clin Pharmacol. 1994;8(2):185-7. [See on PubMed]
  49. Cornu C, Cochat P, Collet JP, Delair S, Haugh MC, Rolland C. Survey of the attitudes to management of acute pyelonephritis in children. GEP. Pediatr Nephrol. 1994;8(3):275-7. [See on PubMed]
  50. Nony P, Girard P, Arnaud P, Rubel P, Fayn J, de Breyne B, et al. Electrophysiologic effects of a potassium channel activator (pinacidil) on repolarization parameters in healthy volunteers: a surface ECG study. J Cardiovasc Pharmacol. 1993;22(4):534-9. [See on PubMed]
  51. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993;23 Suppl 1:89-98. [See on PubMed]
  52. Boissel JP, Haugh MC. The iceberg phenomenon and publication bias: the editors' fault? Clin Trials Metaanal. 1993;28(6):309-15. [See on PubMed]
  53. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ. 1992;305(6859):913-20. [See on PubMed]
  54. Leizorovicz A, Haugh M, Boissel JP. Meta-analysis and multiple publication of clinical trial reports. Lancet. 1992;340(8827):1102-3. [See on PubMed]
  55. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol. 1992;43(3):235-44. [See on PubMed]
  56. Cialdella P, Figon G, Haugh MC, Boissel JP. Prescription intentions in relation to therapeutic information: a study of 117 French general practitioners. Soc Sci Med. 1991;33(11):1263-74. [See on PubMed]
  57. Ulrich J, Haugh M, Anderton BH, Probst A, Lautenschlager C, His B. Alzheimer dementia and Pick's disease: neurofibrillary tangles and Pick bodies are associated with identical phosphorylated neurofilament epitopes. Acta Neuropathol. 1987;73(3):240-6. [See on PubMed]
  58. Anderton BH, Brion JP, Flament-Durand J, Haugh MC, Kahn J, Miller CC, et al. Neurofibrillary tangles and the neuronal cytoskeleton. J Neural Transm Suppl. 1987;24:191-6. [See on PubMed]
  59. Miller CC, Haugh M, Anderton BH, Hudson L, Murphy J. Neurofibrillary tangles from Alzheimer's disease brain purified using a cell sorter. Neurosci Lett. 1986;63(3):247-52. [See on PubMed]
  60. Miller CC, Brion JP, Calvert R, Chin TK, Eagles PA, Downes MJ, et al. Alzheimer's paired helical filaments share epitopes with neurofilament side arms. EMBO J. 1986;5(2):269-76. [See on PubMed]
  61. Haugh MC, Probst A, Ulrich J, Kahn J, Anderton BH. Alzheimer neurofibrillary tangles contain phosphorylated and hidden neurofilament epitopes. J Neurol Neurosurg Psychiatry. 1986;49(11):1213-20. [See on PubMed]
  62. Rasool CG, Abraham C, Anderton BH, Haugh M, Kahn J, Selkoe DJ. Alzheimer's disease: immunoreactivity of neurofibrillary tangles with anti-neurofilament and anti-paired helical filament antibodies. Brain Res. 1984;310(2):249-60. [See on PubMed]
  63. Haugh MC, Cayley PJ, Serafinowska HT, Norman DG, Reese CB, Kerr IM. Analogues and analogue inhibitors of ppp(A2'p)nA. Their stability and biological activity. Eur J Biochem. 1983;132(1):77-84. [See on PubMed]
  64. Haugh M, Anderton B. Relationships of filaments. Nature. 1983;303(5912):21. [See on PubMed]